| scholarly article | Q13442814 |
| P50 | author | Dominique Costagliola | Q33104294 |
| Constance Delaugerre | Q111077180 | ||
| Lise Cuzin | Q41664206 | ||
| Odile Launay | Q65089382 | ||
| P2093 | author name string | Pierre de Truchis | |
| Gilles Pialoux | |||
| Jade Ghosn | |||
| Amélie Menard | |||
| FHDH-ANRS CO4 | |||
| Jean-Marc Lacombe | |||
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America | Q28183380 | ||
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks | Q28269931 | ||
| Raltegravir with optimized background therapy for resistant HIV-1 infection | Q28288290 | ||
| Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients | Q28483630 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r | Q31051809 | ||
| Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials | Q31108441 | ||
| Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study | Q34126545 | ||
| Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. | Q34289633 | ||
| Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial | Q34373867 | ||
| Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study | Q34413527 | ||
| Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial | Q34647153 | ||
| Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010 | Q34702301 | ||
| Maraviroc for previously treated patients with R5 HIV-1 infection | Q34806062 | ||
| Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection | Q35759403 | ||
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Q36198650 | ||
| Class-sparing regimens for initial treatment of HIV-1 infection | Q37454026 | ||
| Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection | Q39570904 | ||
| Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study | Q42285688 | ||
| Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study | Q42678935 | ||
| Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials | Q42711378 | ||
| Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials | Q43189964 | ||
| High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial | Q43265110 | ||
| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial | Q43300648 | ||
| Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. | Q43451461 | ||
| Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 | ||
| Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia | Q44457921 | ||
| Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial | Q44513458 | ||
| Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. | Q45405359 | ||
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d | Q45910955 | ||
| Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibit | Q45987029 | ||
| Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study | Q46414306 | ||
| Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. | Q46492574 | ||
| Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | Q46900196 | ||
| Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study | Q48565770 | ||
| Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. | Q51522370 | ||
| Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. | Q51547763 | ||
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910874 | ||
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910877 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| P304 | page(s) | 463-472 | |
| P577 | publication date | 2014-10-23 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access | |
| P478 | volume | 60 |
| Q40779840 | Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression |
| Q38401143 | Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study |
| Q31074302 | Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra |
| Q55650665 | Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens. |
| Q36294663 | Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study |
| Q38675771 | Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics. |
| Q37034835 | One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: The ACTIVIH study |
| Q56988998 | Residual T cell activation and skewed CD8+ T cell memory differentiation despite antiretroviral therapy-induced HIV suppression |
| Q38406037 | Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4). |
| Q36855625 | Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda |
Search more.